These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 29441438)

  • 1. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
    Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
    Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
    Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib for mantle cell lymphoma.
    Tucker DL; Rule SA
    Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
    Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
    Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
    Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
    Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib for the treatment of mantle cell lymphoma.
    Shah N; Hutchinson C; Rule S
    Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
    Ahmed M; Lorence E; Wang J; Jung D; Zhang L; Nomie K; Wang M
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
    Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
    Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
    Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
    Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
    Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
    Zhao X; Lwin T; Silva A; Shah B; Tao J; Fang B; Zhang L; Fu K; Bi C; Li J; Jiang H; Meads MB; Jacobson T; Silva M; Distler A; Darville L; Zhang L; Han Y; Rebatchouk D; Di Liberto M; Moscinski LC; Koomen JM; Dalton WS; Shain KH; Wang M; Sotomayor E; Tao J
    Nat Commun; 2017 Apr; 8():14920. PubMed ID: 28416797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
    Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
    Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
    Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
    Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.